Kangchen Pharmaceuticals: Clinical trial application for KC1086 tablets officially granted FDA approval.

Kangchen Pharmaceuticals announced that the company has recently received a "Notice of Continued Clinical Research" issued by the US Food and Drug Administration (FDA). The company's application for clinical trials of the KC1086 tablet has officially been granted FDA approval. KC1086 is a small molecule inhibitor of lysine acetyltransferase 6 with a completely new structure developed independently by Beijing Kangchen Pharmaceuticals Co., Ltd. It is intended for the treatment of advanced recurrent or metastatic solid tumors.